insmed inc (IM8N:Frankfurt)
insmed inc (IM8N) Snapshot
|
Open
€9.58
|
Previous Close
€9.40
|
|
|
Day High
€9.58
|
Day Low
€8.60
|
|
|
52 Week High
05/23/13 - €9.61
|
52 Week Low
06/1/12 - €2.21
|
|
|
Market Cap
--
|
Average Volume 10 Days
328.1
|
|
|
EPS TTM
--
|
Shares Outstanding
0.0
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
insmed inc (IM8N) Latest News
insmed inc (IM8N) Related Businessweek News
No Related Businessweek News Foundinsmed inc (IM8N) Details
Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing targeted inhalation therapies for patients battling serious lung diseases. Its lead candidate ARIKACE is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the treatment for two identified patient populations comprising cystic fibrosis (CF) patients with Pseudomonas aeuruginosa lung infections and patients with nontuberculous mycobacteria lung infections (NTM). The company’s Phase III registrational study of ARIKACE in CF patients in Europe and Canada has completed enrollment; and Phase II clinical trial in NTM patients is under way with clinical results. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.
insmed inc (IM8N) Top Compensated Officers
insmed inc (IM8N) Key Developments
Insmed Incorporated Presents at Merrill Lynch 2013 Health Care Conference, May-16-2013 11:20 AM. Venue: Encore at Wynn, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: William H. Lewis, Chief Executive Officer, President and Director.
Insmed Incorporated Presents at UBS Global Healthcare Conference, May-20-2013 02:00 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Andrew T. Drechsler, Chief Financial Officer and Principal Accounting Officer, William H. Lewis, Chief Executive Officer, President and Director.
Insmed Incorporated announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the first quarter of 2013, Insmed posted a net loss of $13.7 million or $0.43 per basic and diluted share compared with a net loss of $6.8 million or $0.28 per basic and diluted share for the first quarter of 2012. Operating loss was $14.3 million against $7.3 million and loss before income taxes was $14.9 million against $6.8 million reported last year. The company estimates that its full year 2013 cash requirements to fund operations will be in the range of $45 million to $55 million. The company expects current cash balances will be sufficient to fund operations into 2014.
| Recently Viewed | |||
| IM8N:GR | €8.60 EUR | -0.80 | |
| Company | Last | Change |
| Gilead Sciences Inc | $55.81 USD | +0.33 |
| Novartis AG | SFr.71.25 CHF | -0.20 |
| View Industry Companies | ||
Industry Analysis
IM8N
Industry Average
| Valuation | IM8N | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 3.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact INSMED INC, please visit www.insmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








